The renin-angiotensin-aldosterone system (RAAS) is intricately involved in the pathophysiology of several diseases, including hypertension, congestive heart failure, and chronic kidney disease of all types, including diabetic nephropathy.Â Pharmaceutical RAAS blockade has is a common and successful strategy in each of these conditions.

As a class, angiotensin receptor blockers, or ARBs, bind to and inhibit the angiotensin II type 1 receptor and are indicated to treat hypertension, congestive heart failure, and diabetic nephropathy.